Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPP5A | Q14642 | 2/20 | 0.57 |
| ▸ | ITPR3 | Q14573 | 7/20 | 0.39 |
| ▸ | ITPR2 | Q14571 | 3/20 | 0.39 |
| ▸ | ITPR1 | Q14643 | 3/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.37 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9414284 | 0.87 | INPP5A (0.70) | INPP5AITPR3ITPR2ITPR1SMPD1 | |
| SCHEMBL10345151 | 0.85 | INPP5A (0.67) | INPP5AITPR3ITPR2ITPR1SMPD1 | |
| SCHEMBL1403803 | 0.85 | INPP5A (0.67) | INPP5AITPR3ITPR2ITPR1SMPD1 | |
| SCHEMBL9414291 | 0.82 | INPP5A (0.71) | INPP5AITPR3ITPR2ITPR1SMPD1 | |
| SCHEMBL9414301 | 0.82 | INPP5A (0.71) | INPP5AITPR3ITPR2ITPR1SMPD1 | |
| SCHEMBL8460802 | 0.82 | INPP5A (0.78) | INPP5AITPR3ITPR2ITPR1SMPD1 | |
| SCHEMBL4456065 | 0.82 | INPP5A (0.78) | INPP5AITPR3ITPR2ITPR1SMPD1 | |
| SCHEMBL10345051 | 0.79 | INPP5A (0.67) | INPP5AITPR3ITPR2ITPR1SMPD1 | |
| SCHEMBL9414309 | 0.77 | INPP5A (0.71) | INPP5AITPR3ITPR2ITPR1SMPD1 | |
| SCHEMBL13497351 | 0.76 | GBA1 (0.35) | INPP5AITPR3ITPR2ITPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9351983-B2 | Use of glycerophosphoinositols for the treatment of septic shock | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2016-05-31 | — | — | US | disclosed |
| US-20150272971-A1 | USE OF GLYCEROPHOSPHOINOSITOLS FOR THE TREATMENT OF SEPTIC SHOCK | DANIELA, CORDA (IT) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150272971-A1 | USE OF GLYCEROPHOSPHOINOSITOLS FOR THE TREATMENT OF SEPTIC SHOCK | PHOSPHO1, PLTP, SGMS1 | INPP5A 120/4885ITPR3 359/4885ITPR2 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.